Passa alle informazioni sul prodotto
GLOW 70mg(10mg BPC157, 10mg TB500, 50mg GHK-CU)
€115,00 EUR
Imposte incluse.
Ritiro non disponibile al momento
NOT FOR HUMAN CONSUMPTION
“GLOW” Peptide Blend (BPC-157 + TB-500 + GHK-Cu)
Additional Benefits of a BPC-157 + TB-500 + GHK-Cu Blend Now Under Investigation
| Benefit | Key take-aways |
|---|---|
| 1 Accelerated wound & incision healing | BPC-157 and TB-500 promote angiogenesis, cell migration, and re-epithelialization; GHK-Cuboosts collagen I/III, GAGs, and MMP/TIMP balance—together shortening closure time and improving early tensile strength in models and small human series. <br/><em>Wound Repair & Regeneration; Burns; Journal of Dermatological Science</em> |
| 2 Tendon/ligament repair | BPC-157 up-regulates FAK/paxillin and VEGFR2/NO pathways; TB-500 enhances actin dynamicsand tenocyte migration—associated with better collagen alignment and load-to-failure in preclinical rotator cuff/Achilles/ACL models. <br/><em>American Journal of Sports Medicine; Journal of Orthopaedic Research</em> |
| 3 Anti-inflammatory, pro-resolution effects | All three peptides down-shift NF-κB/cytokines; palmitoylable copper peptide components (GHK-Cu) add SOD-mimetic/chelation—visible reductions in erythema and edema in cosmetic use. <br/><em>Skin Pharmacology & Physiology; Free Radical Biology & Medicine</em> |
| 4 Scar quality & dermal remodeling | GHK-Cu (with BPC-157/TB-500 angiogenesis) supports organized collagen, elastic fibers, and reduced hypertrophy risk; profilometry shows smoother texture in split-face studies. <br/><em>Clinical, Cosmetic & Investigational Dermatology; Experimental Dermatology</em> |
| 5 Hair & scalp signals (adjunct) | GHK-Cu may stimulate follicular ECM and peri-follicular microvasculature; BPC/TB-500 angiogenesis may complement microneedling/PRP protocols (cosmetic endpoints). <br/><em>Journal of Cosmetic Dermatology; Dermatologic Therapy</em> |
| 6 GI mucosal protection (BPC-157) | Robust rodent data show gastric/colonic ulcer healing, anastomosis strength, and reduced NSAID injury; clinical translation is ongoing. <br/><em>Gut; Pharmacological Reports</em> |
| 7 Nerve/axon support | BPC-157 and TB-500 improve axonal outgrowth and Schwann-cell migration in models—early signals for neuropathic recovery; human evidence limited. <br/><em>Frontiers in Neuroscience; Neuroscience</em> |
| 8 Post-procedure “glow” & downtime | Topical meso/serum GHK-Cu-forward blends reduce post-laser/needling redness and speed visual recovery when used per provider protocol. <br/><em>Journal of Cosmetic Dermatology; Aesthetic Surgery Journal</em> |
| 9 Synergy with rehab | Pairing BPC-157/TB-500 (matrix & angiogenesis) with progressive loading and adequate proteinappears additive in translational paradigms for function and pain reduction. <br/><em>Sports Medicine; Journal of Physiology</em> |
2. Molecular Mechanism of Action
2.1 Pharmacodynamics (by component)
-
BPC-157: Modulates VEGFR2/NO and FAK–paxillin signaling → angiogenesis, cell migration, tight-junctionand mucosal repair; anti-inflammatory via NF-κB restraint.
-
TB-500 (Tβ4 fragment): G-actin sequestration → cell motility, lamellipodia formation; up-regulates VEGF/ILK/integrins; anti-apoptotic and pro-angiogenic in injury beds.
-
GHK-Cu: Copper-bound tripeptide that shifts TGF-β/SMAD, MMP/TIMP and HIF-1/VEGF axes; increases collagen/elastin and keratinocyte migration; antioxidant/chelating activity.
2.2 Down-stream Biology
| Pathway | Functional outcome | Context |
|---|---|---|
| VEGF/VEGFR2 → eNOS/NO | Microvascular growth, perfusion | Wounds, tendon/ligament |
| FAK–paxillin–integrins | Adhesion/migration, matrix attachment | Soft-tissue repair |
| Actin remodeling (TB-500) | Rapid cell motility, re-epithelialization | Dermis/tenocytes |
| TGF-β/SMAD, MMP/TIMP (GHK-Cu) | Balanced remodeling, scar quality | Dermis/ECM |
| NF-κB restraint | ↓ TNF-α/IL-1β/IL-6 | Inflamed tissue/mucosa |
3. Pharmacokinetics
-
Routes used:
-
Topical/mesotherapy (face/scars/scalp) with GHK-Cu-dominant content;
-
Local/peri-lesional injections for soft-tissue research protocols (BPC-157/TB-500).
-
-
Half-lives: Short peptides (minutes–hours) locally; GHK-Cu binds skin proteins and persists longer in upper dermis.
-
Penetration/stability: Improved by palmitoylation, liposomes, or microneedling; copper peptides are pH/oxidation-sensitive (avoid peroxides/strong acids in the same step).
-
Systemic exposure: Low with topical; higher with injections—formal human PK is limited for BPC-157/TB-500.
4. Pre-clinical and Translational Evidence
-
Wound/tendon/ligament: Multiple animal studies show faster closure, greater tensile strength, and better collagen orientation with BPC-157 and TB-500; GHK-Cu adds dermal matrix quality and antioxidant effects.
-
GI: BPC-157 robustly protects gastric/colonic tissue against toxins/NSAIDs and improves anastomosis healing in rodents.
-
Neuro: Axon outgrowth and functional recovery signals appear in nerve-injury models.
-
Aesthetic skin: Split-face/topical studies with GHK-Cu demonstrate improvements in wrinkle depth, elasticity, TEWL, and tone over 8–12 weeks.
Evidence quality note: GHK-Cu has human cosmetic data; BPC-157/TB-500 data are mostly preclinicalwith limited, heterogeneous human reports. High-quality RCTs for the combination are lacking.
5. Emerging Clinical Interests
| Field | Rationale | Status |
|---|---|---|
| Chronic wounds/DFU/VLU | Angiogenesis + remodeling | Pilot/observational |
| Tendinopathy/ligament sprain | Matrix alignment + cell migration | Translational/feasibility |
| Post-procedure aesthetics | Redness down, texture up (GHK-Cu) | Small cosmetic studies |
| Post-op scars | Balanced MMP/TIMP + perfusion | Early programs |
| GI mucosa (BPC-157) | Ulcer/NSAID/inflammation protection | Preclinical → exploratory |
| Peripheral nerve | Axon/Schwann support | Preclinical |
6. Safety and Tolerability
-
Common (topical): Mild stinging, transient erythema/itch; rare contact sensitivity to copper or excipients.
-
Injection-site (research use): Bruising, tenderness, hematoma; infection risk if asepsis lapses.
-
Systemic/theoretical:
-
Pro-angiogenic caution in active malignancy or proliferative retinopathies (theoretical risk).
-
Copper: avoid over-layering with strong acids/oxidizers; rare allergic or blue-green discoloration on fabrics.
-
BPC-157/TB-500: Sparse human safety datasets; avoid in pregnancy/breastfeeding and serious comorbidity outside trials.
-
-
Sport/anti-doping: BPC-157 and TB-500 are prohibited (non-approved peptides/growth factors).
-
Drug interactions: None well characterized; caution with anti-VEGF therapies or anticoagulation (procedure-related bleeding risk).
Comparative safety matrix
| Feature | GHK-Cu (topical) | BPC-157 (inj/topical) | TB-500 (inj) |
|---|---|---|---|
| Regulatory use | Cosmetic ingredient | Research chemical | Research chemical |
| Human evidence | Cosmetic RCTs/split-face | Limited | Limited |
| Main risks | Mild irritation; copper sensitivity | Unknown systemic; site reactions | Unknown systemic; site reactions |
| Pro-angiogenic | Mild/local | Yes (models) | Yes (models) |
7. Regulatory Landscape
-
GHK-Cu: Used legally in cosmetics/OTC topicals (appearance claims only).
-
BPC-157 & TB-500: Not approved as medicines; research-only status; WADA-prohibited.
-
Compounding: Clinic “GLOW” blends vary in identity/purity; no standardized monograph or dosing exists.
8. Practical Use & Future Directions
-
If used cosmetically (topical):
-
AM: gentle cleanse → antioxidant → GHK-Cu serum → moisturizer → broad-spectrum SPF.
-
PM: cleanse → GHK-Cu serum → peptide moisturizer; separate from strong acids/peroxides.
-
-
If studied for soft-tissue repair (research settings): Pair with graded loading/physiotherapy, protein 1.6–2.2 g/kg/d, vitamin C, and sleep optimization; track pain/function and tendon imaging.
-
Research needs: Randomized, controlled trials on the combination, standardized dose/route and quality, tendon/wound biomechanics, and safety (angiogenesis-related, systemic labs).
Selected References
-
Wound Repair & Regeneration; Burns; Journal of Dermatological Science — Dermal healing, collagen organization, and angiogenesis under BPC-157/TB-500/GHK-Cu paradigms.
-
American Journal of Sports Medicine; Journal of Orthopaedic Research — Tendon/ligament models: load-to-failure, collagen alignment, mechanosignaling.
-
Skin Pharmacology & Physiology; Clinical, Cosmetic & Investigational Dermatology — GHK-Cu cosmetic trials (wrinkles, elasticity, TEWL, redness).
-
Free Radical Biology & Medicine; Oxidative Medicine and Cellular Longevity — Copper-peptide antioxidant/chelating behavior and redox biology.
-
Gut; Pharmacological Reports — BPC-157 gastroprotection/anastomosis strength in preclinical studies.
-
Frontiers in Neuroscience; Neuroscience — Axonal outgrowth and neurorepair signals with BPC-157/Tβ4 derivatives.
-
Sports Medicine; Journal of Physiology — Rehab synergy with matrix/angiogenic cues
